We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$661M
AUM Growth
+$34.1M
Cap. Flow
-$6.85M
Cap. Flow %
-1.04%
Top 10 Hldgs %
25.72%
Holding
101
New
10
Increased
24
Reduced
44
Closed
5

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$12.3M
2
ABMD
Abiomed Inc
ABMD
+$12.2M
3
WBA
Walgreens Boots Alliance
WBA
+$11.2M
4
CVS icon
CVS Health
CVS
+$8.13M
5
BHC icon
Bausch Health
BHC
+$7.75M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.33M
2
ALKS icon
Alkermes
ALKS
+$6.79M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.92M
4
HCA icon
HCA Healthcare
HCA
+$5.86M
5
EW icon
Edwards Lifesciences
EW
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
76
Rigel Pharmaceuticals
RIGL
$750M
$2.56M 0.39%
84,431
-8,069
-9% -$245K
CLVS
77
DELISTED
Clovis Oncology, Inc.
CLVS
$2.56M 0.39%
73,000
+30,000
+70% +$1.93M
CYH icon
78
Community Health Systems
CYH
$423M
$2.52M 0.38%
114,950
-151,250
-57% -$3.91M
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.56B
$2.47M 0.37%
20,900
– –
ATXS
80
DELISTED
Astria Therapeutics
ATXS
$2.43M 0.37%
5,104
+97
+2% +$46.5K
SGNT
81
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$2.39M 0.36%
+150,000
New +$2.36M
OMCL icon
82
Omnicell
OMCL
$1.68B
$2.3M 0.35%
74,000
– –
CMRX
83
DELISTED
Chimerix, Inc.
CMRX
$2.29M 0.35%
256,000
+200,000
+357% +$7.2M
TTPH
84
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.26M 0.34%
11,250
– –
ESPR
85
DELISTED
Esperion Therapeutics
ESPR
$2.23M 0.34%
100,000
– –
OREX
86
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.04M 0.31%
118,900
– –
RGLS
87
DELISTED
Regulus Therapeutics
RGLS
$1.74M 0.26%
1,667
– –
MRTX
88
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.58M 0.24%
50,000
– –
ARRY
89
DELISTED
Array Biopharma Inc
ARRY
$1.56M 0.24%
370,000
– –
KYNB
90
Kyntra Bio
KYNB
$29.4M
$1.52M 0.23%
+2,000
New +$1.33M
ADVM
91
DELISTED
Adverum Biotechnologies
ADVM
$1.47M 0.22%
15,401
– –
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$1.33M 0.2%
55,000
– –
HOLX
93
DELISTED
Hologic
HOLX
$1.29M 0.19%
33,301
– –
ANTH
94
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.16M 0.18%
31,250
– –
BIND
95
DELISTED
BIND THERAPEUTICS INC
BIND
$306K 0.05%
133,535
– –
MTEM
96
DELISTED
Molecular Templates, Inc.
MTEM
$97K 0.01%
1,221
– –
LXRX icon
97
Lexicon Pharmaceuticals
LXRX
$1.1B
– –
-200,000
Closed -$2.15M
MRK icon
98
Merck
MRK
$318B
– –
-104,800
Closed -$4.94M
VTRS icon
99
Viatris
VTRS
$18.9B
– –
-100,000
Closed -$4.03M
KITE
100
DELISTED
Kite Pharma, Inc.
KITE
– –
-57,000
Closed -$3.17M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rhenman & Partners Asset Management held 101 positions worth $661M, up 5.4% from $627M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q4 2015 filing shows 10 new, 24 increased, 44 reduced and 5 closed positions. Its largest new stake was Walgreens Boots Alliance: 132,000 shares worth $11.2M. The largest sale was Amgen, an estimated $8.33M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q4 2015 buy was Walgreens Boots Alliance: 132,000 shares worth $11.2M.
  • Rhenman & Partners Asset Management added most to Perrigo in Q4 2015, an estimated $12.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2015 reduction was Amgen, cutting an estimated $8.33M.
  • Rhenman & Partners Asset Management fully exited Merck in Q4 2015, selling an estimated $4.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $661M portfolio in Q4 2015.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q4 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $661M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.